Behcet’s (beh-CHETS) disease, also called Behcet’s syndrome, is a rare disorder that causes blood vessel inflammation throughout your body.
The disease can lead to numerous signs and symptoms that may seem unrelated at first. They may include mouth sores, eye inflammation, skin rashes and lesions, and genital sores.
The effects of Behcet’s disease vary from person to person and may clear up on their own.
Treatment involves medications to reduce the signs and symptoms of Behcet’s disease and to prevent serious complications, such as blindness.
The FDA has moved from a review to a formal proposal to withdraw approval of Tavneos in the United States.
This is a more serious step than a review, but it is still not a final decision.
In Europe, the EMA review is still ongoing. No conclusions have been reached yet, and Tavneos is still available.
The U.S. Food and Drug Administration (FDA) issued a Drug Safety
Communication on 31 March 2026, alerting healthcare professionals and patients to serious cases of drug-induced liver injury (DILI) in postmarketing surveillance of avacopan — including cases with fatal outcomes.
While the FDA operates outside the European regulatory framework,
its postmarketing findings are directly relevant to the EMA’s ongoing assessment.
Rare Disease Day is marked every year on the last day of February. On this day, patients, families, healthcare professionals and organisations around the world come together to raise awareness about rare diseases and the people living with them.
